- Home
- FLR vs NUVL Comparison
FLR vs NUVL Comparison
Compare FLR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLR
- NUVL
- Stock Information
- Founded
- FLR 1912
- NUVL 2017
- Country
- FLR United States
- NUVL United States
- Employees
- FLR N/A
- NUVL N/A
- Industry
- FLR Military/Government/Technical
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FLR Industrials
- NUVL Health Care
- Exchange
- FLR Nasdaq
- NUVL Nasdaq
- Market Cap
- FLR 6.4B
- NUVL 5.6B
- IPO Year
- FLR N/A
- NUVL 2021
- Fundamental
- Price
- FLR $37.20
- NUVL $70.46
- Analyst Decision
- FLR Strong Buy
- NUVL Strong Buy
- Analyst Count
- FLR 7
- NUVL 10
- Target Price
- FLR $54.71
- NUVL $113.10
- AVG Volume (30 Days)
- FLR 2.7M
- NUVL 594.2K
- Earning Date
- FLR 05-02-2025
- NUVL 05-08-2025
- Dividend Yield
- FLR N/A
- NUVL N/A
- EPS Growth
- FLR 2177.78
- NUVL N/A
- EPS
- FLR 12.30
- NUVL N/A
- Revenue
- FLR $16,315,000,000.00
- NUVL N/A
- Revenue This Year
- FLR $13.71
- NUVL N/A
- Revenue Next Year
- FLR $5.77
- NUVL N/A
- P/E Ratio
- FLR $3.02
- NUVL N/A
- Revenue Growth
- FLR 5.43
- NUVL N/A
- 52 Week Low
- FLR $34.01
- NUVL $61.80
- 52 Week High
- FLR $60.10
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FLR 45.41
- NUVL 39.36
- Support Level
- FLR $34.69
- NUVL $67.47
- Resistance Level
- FLR $39.14
- NUVL $77.93
- Average True Range (ATR)
- FLR 1.15
- NUVL 3.15
- MACD
- FLR 0.28
- NUVL -0.44
- Stochastic Oscillator
- FLR 56.40
- NUVL 26.88
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. The firm serves a wide range of end markets including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.